Design and recruitment
cutaneous lesion
MUSCLE WEAKNESS, PATHOLOGY
We conducted a single centre, double-blind randomised controlled trial with intention to treat analysis in our 18 bed ICU at Le Havre Hospital in France. We recruited consecutive individuals with a diagnosis that did not involve covid-19, who were admitted to our ICU between December 2019 and July 2022. The inclusion criteria were aged > 18 years, ventilated for at least 24 h with an expected stay of more than 72 h in the unit. The patients were required to be fully independent prior to admission to the ICU. The exclusion criteria were having been hospitalised for > 72 h before ICU admission, having a pacemaker or an implantable defibrillator, a cutaneous lesion that could interfere with probes, neurological pathology with disabling muscle weakness, chronic loss of autonomy (defined by a Katz score below 6/6), BMI > 35 kg/mEthical approval was granted by the French Comité de Protection des Personnes Ile de France X (38-19). All participants or their relatives provided written informed consent for participation. This study was prospectively registered (NCT04171024) and is reported according to the CONSORT guidelines.Randomisation was performed by a computer-generated random number sequence (